Drug Profile
Tirabrutinib - Gilead Sciences/Ono Pharmaceutical
Alternative Names: GS-4059; ONO-4059; Tirabutinib hydrochloride - Gilead Sciences/Ono Pharmaceutical; VelexbruLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Developer Gilead Sciences; Ono Pharmaceutical
- Class Alkynes; Amines; Antineoplastics; Antirheumatics; Ketones; Phenyl ethers; Purines; Pyrrolidines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Lymphoma
- Registered Waldenstrom's macroglobulinaemia
- Phase III Pemphigus
- Phase II B-cell lymphoma; Chronic lymphocytic leukaemia
- No development reported Scleroderma
- Discontinued Chronic urticaria; Rheumatoid arthritis; Sjogren's syndrome
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Scleroderma in Japan (PO)
- 02 Jun 2023 Updated adverse events and efficacy data from a phase I/II trial in Lymphoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 21 Mar 2023 Tirabrutinib - Gilead Sciences/Ono Pharmaceutical receives Orphan Drug status for Lymphoma in USA